Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy

Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy

IntroductionImmunotherapy with checkpoint inhibitors is an efficient treatment for metastatic melanoma. Development of vitiligo upon immunotherapy represents a specific immune-related adverse event (irAE) diagnosed in 15% of patients and associated with a positive clinical response. Therefore, a det...

Full description

Bibliographic Details
Main Authors: Maria Luigia Carbone, Alessia Capone, Marika Guercio, Sofia Reddel, Domenico Alessandro Silvestris, Daniela Lulli, Carmela Ramondino, Daniele Peluso, Concetta Quintarelli, Elisabetta Volpe, Cristina Maria Failla
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
melanoma
immunotherapy
vitiligo
biomarkers
T-cell receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1197630/full

Similar Items

Similar Items